Drugs / N-acetylcisteine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT05340634 | Apr 2020 → Feb 2022 | polycystic ovary syndrome | Margan Biotech | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT01594489 Comparator | Jan 2009 → Sep 2012 | acute kidney injury | Ospedale Misericordia e Dolce | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | N-acetylcisteine | “200 mg S-adenosylmethionine, 100 mg N-acetylcisteine, 75 mg alpha lipoid acid and 0,65 mg vitamin B6” NCT05340634 ↗ |
| Known as | N-acetilcysteine | “N-acetilcysteine: intravenous bolus of 1200 mg before angioplasty and 1200 mg twice daily for the 48 hours after PCI” NCT01594489 ↗ |
| Modality | Other / unclassified | “as a dietary supplement” NCT05340634 ↗ |
| Route | Intravenous | “N-acetilcysteine: intravenous bolus” NCT01594489 ↗ |